Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
CymaBay Therapeutics Inc is a biotechnology business based in the US. CymaBay Therapeutics shares (CBAY) are listed on the NASDAQ and all prices are listed in US Dollars. CymaBay Therapeutics employs 41 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$4.01|
|52-week range||$3.39 - $9.06|
|50-day moving average||$3.88|
|200-day moving average||$4.17|
|Wall St. target price||$10.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.99|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||4.01|
|1 month (2021-09-23)||3.08%|
|3 months (2021-07-23)||-2.91%|
|6 months (2021-04-23)||-9.68%|
|1 year (2020-10-23)||-55.59%|
|2 years (2019-10-23)||-18.99%|
|3 years (2018-10-23)||10.24|
|5 years (2016-10-21)||134.50%|
|Gross profit TTM||$-22,893,000|
|Return on assets TTM||-29.42%|
|Return on equity TTM||-49.83%|
|Market capitalisation||$276.7 million|
TTM: trailing 12 months
There are currently 2.2 million CymaBay Therapeutics shares held short by investors – that's known as CymaBay Therapeutics's "short interest". This figure is 17.6% down from 2.6 million last month.
There are a few different ways that this level of interest in shorting CymaBay Therapeutics shares can be evaluated.
CymaBay Therapeutics's "short interest ratio" (SIR) is the quantity of CymaBay Therapeutics shares currently shorted divided by the average quantity of CymaBay Therapeutics shares traded daily (recently around 326902.88753799). CymaBay Therapeutics's SIR currently stands at 6.58. In other words for every 100,000 CymaBay Therapeutics shares traded daily on the market, roughly 6580 shares are currently held short.
However CymaBay Therapeutics's short interest can also be evaluated against the total number of CymaBay Therapeutics shares, or, against the total number of tradable CymaBay Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CymaBay Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 CymaBay Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0425% of the tradable shares (for every 100,000 tradable CymaBay Therapeutics shares, roughly 43 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CymaBay Therapeutics.
Find out more about how you can short CymaBay Therapeutics stock.
We're not expecting CymaBay Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, CymaBay Therapeutics's shares have ranged in value from as little as $3.39 up to $9.06. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CymaBay Therapeutics's is 1.1852. This would suggest that CymaBay Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
CymaBay Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases; and holds a worldwide license from Janssen Pharmaceuticals, Inc.
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Oct. 21, 2021
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.